Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment

CLICK HERE TO DOWNLOAD THE PDF

 

Publication Date: March 2007 /
Author: I. Catza / K.G. Warrena / L.Z. Ferenczib / M.J. Krantz /
Categories: Drugs / Journal Articles / Specific to MS /

2018-01-17T17:03:01+00:00
MAKE A DONATION